Biosimilars represent one of the pillars of Actavis’ strategy to drive long-term growth. We are committed to building a leadership position in this emerging global market.
Our biosimilar product pipeline currently consists of four oncology products being developed in collaboration with Amgen, including biosimilar versions of Herceptin®, Avastin®, Rituxan/Mab Thera®, and Erbitux®. These products represent some of the fastest-growing pharmaceutical products in the world with peak innovator sales topping $20 billion.
This collaboration places Amgen and Actavis in an unparalleled position in the global biosimilars market by capitalizing on best-in-class capabilities in both innovative biologics and specialty branded and generics pharmaceuticals.
It delivers on Actavis’ promise to be a leader in the field of biosimilars, and does so in a way that helps manage the substantial financial investment, operational capabilities and broad commercial skills required to bring safe, high-quality and cost-effective biosimilar therapies to patients.